Current therapy for brain tumors: Back to the future

Archives of Neurology

Volumn 56, Issue 4, 1999, Pages 429-432

  Shapiro, William R ^a  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; CARMUSTINE; CISPLATIN; CRM 107; ETOPOSIDE; FUMAGILLOL CHLOROACETYLCARBAMATE; LEFLUNOMIDE; MONOCLONAL ANTIBODY; MUTANT PROTEIN; PACLITAXEL; TAMOXIFEN; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG;

BEAM THERAPY; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; GENE THERAPY; GENETIC HETEROGENEITY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LASER SURGERY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0032893488     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.4.429     Document Type: Review

References (25)

1. Hochberg FH, Pruitt AA. Assumptions in the radiotherapy of glioblastoma. Neurology. 1980;30:907-911.
2. Albert FK, Forsting M, Sartor K, Adams HP, Kunze S. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence or regrowth and prognosis. Neurosurgery. 1994;34:45-61.
3. Berger MS, Deliganis AV, Dobbins J, Keles GE. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer. 1994;74:1784-1791.
4. Wood JR, Green SB, Shapiro WR. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol. 1988;6:338-343.
5. Shapiro WR, Green SB, Burger PC, etal. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma: Brain Tumor Cooperative Group Trial 8001. J Neurosurg. 1989;71:1-9.
6. Shapiro WR, Green SB, Burger P, et al. A randomized trial of interstitial radiotherapy (IRT) boost for the treatment of newly diagnosed malignant glioma (glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, malignant mixed glioma): BTCG study 8701 [abstract]. Neurology. 1994;44(suppl 2):263.
7. Green SB, Byar DP, Walker MD, et al. Comparisons of carmustine, procarbazine and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep. 1983;67:121-132.
8. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet. 1995;345:1008-1012.
9. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst. 1990;82:297-300.
10. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 1992;256:1550-1552.
11. Ram Z, Walbridge S, Shawker T, Culver KW, Blaese RM, Oldfield EH. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neumsurg. 1994;81:256-260.
12. Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med. 1997:3: 1354-1361.
13. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med. 1997;3:1362-1368.
14. Burger PC. Pathologic anatomy and CT correlations in the glioblastoma multiforme. Appl Neurophysiol. 1983;46:180-187.
15. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy tor anaplastic oligodendroglioma. J Clin Oncol. 1994;12:2013-2021.
16. Shapiro JR, Yung WA, Shapiro WR. Isolation, karyotype and clonal growth of heterogeneous subpopulations of human malignant gliomas. Cancer Res. 1981; 41:2349-2359.
17. Shapiro JR, Pu P, Mohamed AN, et al. Chromosome number and carmustine sensitivity in human gliomas. Cancer. 1993;71:4007-4021.
18. Scheck AC, Shapiro JR, Coons SW, Norman SA, Johnson PC. Biological and molecular analysis of a low-grade recurrence of a glioblastoma multilorme. Clin Cancer Res. 1996;2:187-199.
19. Shapiro WR, Green SB, Burger PC, et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg. 1992;76:772-781.
20. Rosenblum MK, Delattre JY, Walker RW, Shapiro WR. Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study. J Neurooncol. 1989;7:269-281.
21. Neuwelt EA, Howieson J, Frenkel EP, et al. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery. 1986;19:573-582.
22. Fetell MR, Grossman SA, Fisher JD, et al. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. J Clin Oncol. 1997;15:3121-3128.
23. Gutin PH, Prados MD, Phillips TL, et al. External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2. Int J Radiat Oncol Biol Phys. 1991;21: 601-606.
24. Edwards MSB, Wara WM, Urtasun RC, et al. Hyperfractionated radiation for brainstem glioma: a phase I-II trial. J Neurosurg. 1989;70:691-700.
25. Shrieve DC, Wara WM, Edwards MSB, et al. Hyperfractionated radiation therapy for gliomas of the brainstem in children and in adults. Int J Radiat Oncol Biol Phys. 1992;24:599-610.